News articles about Stellar Biotechnologies (NASDAQ:SBOT) have trended positive on Wednesday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Stellar Biotechnologies earned a daily sentiment score of 0.41 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 47.0893455733163 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Stellar Biotechnologies (NASDAQ SBOT) opened at $0.80 on Wednesday. Stellar Biotechnologies has a 12 month low of $0.75 and a 12 month high of $2.05. The company has a market cap of $8.64, a P/E ratio of -1.67 and a beta of 0.90.
Stellar Biotechnologies (NASDAQ:SBOT) last issued its earnings results on Wednesday, February 7th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Stellar Biotechnologies had a negative net margin of 4,579.63% and a negative return on equity of 62.27%. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.05 million. equities analysts predict that Stellar Biotechnologies will post -0.48 earnings per share for the current fiscal year.
Stellar Biotechnologies Company Profile
Stellar Biotechnologies, Inc is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases.
Receive News & Ratings for Stellar Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellar Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.